{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T22:27:40Z","timestamp":1793485660419,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s13300-020-00771-8","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T10:02:52Z","timestamp":1581501772000},"page":"711-723","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["SGLT2 Inhibitors and the Risk of Hospitalization for Fournier\u2019s Gangrene: A Nested Case\u2013Control Study"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7621-7781","authenticated-orcid":false,"given":"Tongtong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrita M.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Hickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip LStJ","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Gantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol E.","family":"Koro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,12]]},"reference":[{"key":"771_CR1","unstructured":"European Medicines Agency. PRAC recommendations on signals. Adopted at the 26\u201329 November 2018 PRAC meeting. https:\/\/www.ema.europa.eu\/en\/documents\/other\/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-november-2018_en.pdf. Accessed July 14, 2019."},{"key":"771_CR2","unstructured":"US Food and Drug Administration. FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm617360.htm. Accessed July 14, 2019."},{"issue":"3","key":"771_CR3","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000445695","volume":"97","author":"MD Sorensen","year":"2016","unstructured":"Sorensen MD, Krieger JN. Fournier\u2019s gangrene: epidemiology and outcomes in the general US population. Urol Int. 2016;97(3):249\u201359.","journal-title":"Urol Int"},{"issue":"4","key":"771_CR4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.surge.2013.02.001","volume":"11","author":"DC Shyam","year":"2013","unstructured":"Shyam DC, Rapsang AG. Fournier\u2019s gangrene. Surgeon. 2013;11(4):222\u201332.","journal-title":"Surgeon"},{"key":"771_CR5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ijsu.2017.02.067","volume":"40","author":"T Yilmazlar","year":"2017","unstructured":"Yilmazlar T, Gulcu B, Isik O, Ozturk E. Microbiological aspects of Fournier\u2019s gangrene. Int J Surg. 2017;40:135\u20138.","journal-title":"Int J Surg"},{"issue":"2","key":"771_CR6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/cid\/ciu444","volume":"59","author":"DL Stevens","year":"2014","unstructured":"Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):147\u201359.","journal-title":"Clin Infect Dis"},{"key":"771_CR7","first-page":"e18","volume":"15","author":"LS Karian","year":"2015","unstructured":"Karian LS, Chung SY, Lee ES. Reconstruction of defects after Fournier gangrene: a systematic review. Eplasty. 2015;15:e18.","journal-title":"Eplasty"},{"issue":"6","key":"771_CR8","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1046\/j.1365-2168.2000.01497.x","volume":"87","author":"N Eke","year":"2000","unstructured":"Eke N. Fournier\u2019s gangrene: a review of 1726 cases. Br J Surg. 2000;87(6):718\u201328.","journal-title":"Br J Surg"},{"issue":"8","key":"771_CR9","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S0210-4806(09)72875-X","volume":"33","author":"RM Chinchilla","year":"2009","unstructured":"Chinchilla RM, Morejon EI, Pietricica BN, Franco EP, Albasini JLA, Lopez BM. Fournier\u2019s gangrene. Descriptive analysis of 20 cases and literature review. Actas Urol Esp. 2009;33(8):873\u201380.","journal-title":"Actas Urol Esp"},{"key":"771_CR10","volume-title":"Emergencies in urology","author":"CF Heyns","year":"2007","unstructured":"Heyns CF. Theron PD. Fournier\u2019s gangrene. In: Hohenfellner M, Santucci RA, editors. Emergencies in urology. Berlin: Springer; 2007."},{"key":"771_CR11","unstructured":"Pais VM, Santora TA, Rukstalis DB, Sollender GE. https:\/\/emedicine.medscape.com\/article\/2028899-overview. Accessed July 14, 2019."},{"issue":"4","key":"771_CR12","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0210-4806(00)72452-1","volume":"24","author":"A Rodr\u00edguez Alonso","year":"2000","unstructured":"Rodr\u00edguez Alonso A, P\u00e9rez Garc\u00eda MD, N\u00fa\u00f1ez L\u00f3pez A, et al. Fournier\u2019s gangrene: anatomo-clinical features in adults and children. Therapy update. Actas Urol Esp. 2000;24(4):294\u2013306.","journal-title":"Actas Urol Esp"},{"issue":"4","key":"771_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"22","key":"771_CR14","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"771_CR15","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"24","key":"771_CR16","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"11","key":"771_CR17","doi-asserted-by":"publisher","first-page":"764","DOI":"10.7326\/M19-0085","volume":"170","author":"Susan J. Bersoff-Matcha","year":"2019","unstructured":"Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. Ann Intern Med. 2019;170(11):764\u20139.","journal-title":"Annals of Internal Medicine"},{"issue":"11","key":"771_CR18","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1001\/jamainternmed.2019.2813","volume":"179","author":"CV Dave","year":"2019","unstructured":"Dave CV, Schneeweiss S, Patorno E. Association of sodium-glucose cotransporter\u00a02 inhibitor treatment with risk of hospitalization for Fournier gangrene among men. JAMA Intern Med. 2019;179(11):1587\u201390.","journal-title":"JAMA Intern Med"},{"key":"771_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13886","author":"N Petruski-Ivleva","year":"2019","unstructured":"Petruski-Ivleva N, Schneeweiss S, Eapen S, Rajan A, Jan S. Fournier\u2019s gangrene in patients with type 2 diabetes using second-line antidiabetic medications. Diabetes Obes Metab. 2019. https:\/\/doi.org\/10.1111\/dom.13886.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"771_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jinf.2017.09.015","volume":"76","author":"L Chia","year":"2018","unstructured":"Chia L, Crum-Cianflone NF. Emergence of multi-drug resistant organisms (MDROs) causing Fournier\u2019s gangrene. J Infect. 2018;76(1):38\u201343.","journal-title":"J Infect"},{"key":"771_CR21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40064-014-0783-8","volume":"4","author":"LM Tang","year":"2015","unstructured":"Tang LM, Su YJ, Lai YC. The evaluation of microbiology and prognosis of Fournier\u2019s gangrene in past five years. SpringerPlus. 2015;4:14.","journal-title":"SpringerPlus"},{"issue":"9468","key":"771_CR22","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/S0140-6736(05)66379-9","volume":"365","author":"DA Grimes","year":"2005","unstructured":"Grimes DA, Schulz KF. Compared to what? Finding controls for case-control studies. Lancet. 2005;365(9468):1429\u201333.","journal-title":"Lancet"},{"issue":"4","key":"771_CR23","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/pds.1549","volume":"17","author":"LH Nielsen","year":"2008","unstructured":"Nielsen LH, Lokkegaard E, Andreasen AH, Keiding N. Using prescription registries to define continuous drug use: how to fill gaps between prescriptions. Pharmacoepidemiol Drug Saf. 2008;17(4):384\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"771_CR24","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"41","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D\u2019Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669\u2013701.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"771_CR25","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.2337\/dc19-S009","volume":"42","author":"American Diabetes Association","year":"2019","unstructured":"American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S90\u2013102.","journal-title":"Diabetes Care"},{"key":"771_CR26","first-page":"811","volume-title":"Pharmacoepidemiology","author":"S Suissa","year":"2005","unstructured":"Suissa S. Novel approaches to pharmacoepidemiology study design and statistical analysis. In: Strom BL, editor. Pharmacoepidemiology. 4th ed. New York: Wiley; 2005. p. 811\u201329.","edition":"4"},{"issue":"1","key":"771_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1471-2288-5-5","volume":"5","author":"V Essebag","year":"2005","unstructured":"Essebag V, Platt RW, Abrahamowicz M, Pilote L. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol. 2005;5(1):5.","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"771_CR28","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676\u201382.","journal-title":"Am J Epidemiol"},{"issue":"6","key":"771_CR29","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1001\/archinternmed.2011.89","volume":"171","author":"S Weiss-Smith","year":"2011","unstructured":"Weiss-Smith S, Deshpande G, Chung S, Gogolak V. The FDA drug safety surveillance program: adverse event reporting trends. Arch Intern Med. 2011;171(6):591\u20133.","journal-title":"Arch Intern Med"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-020-00771-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-020-00771-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-020-00771-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:15:31Z","timestamp":1724411731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-020-00771-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,12]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["771"],"URL":"https:\/\/doi.org\/10.1007\/s13300-020-00771-8","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,12]]},"assertion":[{"value":"4 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}